bluebird bio Stock News

Bluebird (BLUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro

Investors seeking opportunities among growth stocks could be interested in the following small caps, as they represent companies whose trailing 12-month net income per share has improved significantly

Investors, prodded by analysts, warmed up to the company after another FDA-approved therapy.

bluebird's (BLUE) Syskona (eli-cel) gets FDA approval for early, active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.

Yahoo Finance's Brad Smith and Julie Hyman discusses the reversal in Bluebird Bio shares after the FDA approved its second gene therapy.

Bluebird Bio Inc (NASDAQ:BLUE) is in the spotlight today, after the U.S. Food and Drug Administration (FDA) approved SKYSONA, its gene therapy for the treatment of Cerebral Adrenoleukodystrophy (CAL

The company anticipates the product to be available by the end of 2022.

Is it worth taking a chance on these stocks?

Think twice before investing in these companies.

Biotech stocks are scorching right now. But the best of the best have strong gains.

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.

This biotech really needed some good news.

bluebird bio has a lot of future potential, but no guarantees. A look at whether the risk outweighs the potential rewards.

Analysts were lukewarm on the seemingly very positive news reported by the company midweek.